ArticleInternational journal of molecular sciences2019
In Vitro Entero-Capillary Barrier Exhibits Altered Inflammatory and Exosomal Communication Pattern after Exposure to Silica Nanoparticles.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Amorphous silica nanoparticles and the human gut microbiota: a relationship with multiple implications.Journal of nanobiotechnology · 2024Review
- An Adverse Outcome Pathway for food nanomaterial-induced intestinal barrier disruption.Frontiers in toxicology · 2024Article
- Macrophages Release Extracellular Vesicles of Different Properties and Composition Following Exposure to Nanoparticles.International journal of molecular sciences · 2022Article
- Pharmacokinetics of PEGylated Gold Nanoparticles: In Vitro-In Vivo Correlation.Nanomaterials (Basel, Switzerland) · 2022Article
- Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics.Theranostics · 2022Review
- Mechanisms of immune response to inorganic nanoparticles and their degradation products.Advanced drug delivery reviews · 2022Review
- Exosomes as a New Delivery Vehicle in Inflammatory Bowel Disease.Pharmaceutics · 2021Review
- Exosomes in osteoarthritis and cartilage injury: advanced development and potential therapeutic strategies.International journal of biological sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intestinal microvasculature (iMV) plays multiple pathogenic roles during chronic inflammatory bowel disease (IBD). The iMV acts as a second line of defense and is, among other factors, crucial for the innate immunity in the gut. It is also the therapeutic location in IBD targeting aggravated leukocyte adhesion processes involving ICAM-1 and E-selectin. Specific targeting is stressed via nanoparticulate drug vehicles. Evaluating the iMV in enterocyte barrier models in vitro could shed light on inflammation and barrier-integrity processes during IBD. Therefore, we generated a barrier model by combining the enterocyte cell line Caco-2 with the microvascular endothelial cell line ISO-HAS-1 on opposite sides of a transwell filter-membrane under culture conditions which mimicked the physiological and inflamed conditions of IBD. The IBD model achieved a significant barrier-disruption, demonstrated via transepithelial-electrical resistance (TER), permeability-coefficient (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.